Biosimilars Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

 Biosimilars Market Scenario

Biosimilars Market Size is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1329 

For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.

For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn’s disease (CD), and plaque psoriasis (Ps)

Biosimilars Market Segmentation

Global Biosimilars Market has been segmented based on product, applications, end users, and region.

The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.

The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin

The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  

For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.

On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.

For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.

Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.

Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.

The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Biosimilars Market Key Players

The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).

Regional Market Summary

The market in Europe is expected to dominate the global biosimilars market due to the increasing biosimilar product approvals and the emergence of new market participants in the region. The growing prevalence of chronic diseases in the US and Canada is expected to drive the market growth. Furthermore, there has been an increase in the expenditure in research by healthcare bodies; this is expected to fuel the growth of the market in this region. For example, according to Amgen, in 2019, Europe has an advanced biosimilar market, with 53 approved biosimilar products. The market in Asia-Pacific expected to show a considerable amount of growth. This can be attributed to the patent expiry of biologic products, introduction of new biosimilars, adoption of biosimilars to reduce the treatment cost, and the involvement of key companies. For instance, according to the National Center for Biotechnology Information, in 2019, Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop similar biologics. Already there are more than 100 Indian biopharmaceutical companies are engaged in manufacturing and marketing of biosimilar. The market in Americas is projected to have a steady growth rate during the forecast period owing to an increase in chronic diseases and well-developed healthcare system. The market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329 

Erectile Dysfunction Drugs Market Staggering Double Digit Cagr Till 2023

 Erectile Dysfunction Drugs Market Overview: 

The global market for erectile dysfunction drugs market is set to cross a valuation of USD 2930million by 2023 with a CAGR of 3.5% during the forecast period (2018-2023). Market Research Future revealed several factors like a rising recording of cases of erectile disorder, increasing geriatric population, expiry of patents of major blockbuster drugs, and better drug development as major reasons behind the growth of the erectile dysfunction drugs market. Growth in the sedentary lifestyle may also boost the demand for such drugs.  

However, patients often fail to adhere to these drugs in proper terms, which can restrain the growth of this erectile dysfunction drug market growth.  

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1313

Erectile Dysfunction Drugs Market Segmentation: 

The global erectile dysfunction drugs market, on account of MRFR experts, has been segmented based on drugs and end users. This segmentation is expected to reveal insight related to dynamics, growth factors, and demographic challenges. These insights will be further backed by figures received after detailed analysis.  

By drug, the global market on the erectile dysfunction drugs has been segmented into Cialis (tadalafil), staxyn/Levitra (vardenafil), viagra (sildenafil citrate), zydena (udenafil), vitaros (alprostadil cream), stendra/spedra (avanafil), and others. Viagra has a huge market share as it is the first-of-its-kind drug that received the approval of the FDA in 1998. Cialis is expected to make a better impact on the market in terms of growth as its erection period is higher than that of Viagra.  

By end user, the global market for erectile dysfunction drugs has been segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is expected to benefit from the easy availability of drugs. The segment is the largest one. Hospitals are expected to gain more from growing awareness and are expected to be the fastest one in terms of growth.  

Erectile Dysfunction Drugs Market Regional Analysis: 

The Americas are set to dominate the global erectile dysfunction drugs market. This is primarily due to the rising presence of major drug companies and the increasing adoption of various new technologies to treat the disorder. Also, the growing awareness regarding the disorder is expected to boost the market profit. In Asia Pacific, rising awareness and the massive population are expected to play in favor of the market.  

Erectile Dysfunction Drugs Market Competitive Landscape: 

Global erectile dysfunction drugs market is expected to get boosted by the strategic developments launched by companies like Apricus Biosciences Inc., Bayer AG, Pfizer, Inc., Dong-A Pharmaceutical Co. Ltd., Cristalia Produtos Quimicos Farmaceuticos Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Vivus, Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and others. These companies are showing an intent to take the global market forward by constantly indulging in various strategic discussions where they are working on mergers, acquisitions, collaborations, hike in investment for research and development, branding strategies, distribution channels, and others. MRFR’s recording of all the latest proceedings is expected to improve the scope of market study.  

Industry News: 

In May 2020, a report revealed that the global market for erectile dysfunction drugs market had witnessed a price fall in both generic and branded drugs between July 2019 and January 2020. But the price of branded drugs has bounced back after February 2020. The report is on the basis of a close analysis of several online drug supply chain. One of the major reasons behind this price change is COVID-19. The rise in home delivery services has changed the market expectations and the price is getting impacted by that.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

…Continued 

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313 

Dental Infection Treatment Market 2020: Global Industry Analysis and Opportunity Assessment, Forecast to 2023

 Market scenario:

Dental infection or tooth abscess is the infection of teeth, gums and associated tissue caused by a bacterial infection. The abscess can occur at different regions such as periapical abscess occurring at the tip of the root, and a periodontal abscess occurring in the gums next to a tooth root. Tooth abscess leads to pus formation and if left untreated can lead to serious, even life-threatening, complications. The symptoms of a tooth abscess include severe, persistent, throbbing pain in the tooth which can radiate to the jawbone, neck and other associated parts of the head, fever, swelling in cheeks, swollen lymph nodes, sensitivity to hot and cold foods etc. The spread of infection results in foul smell and foul-taste in mouth. The periapical tooth abscess is the most dangerous as bacteria invade the dental pulp which is the innermost part of the tooth that contains blood vessels, nerves and connective tissue.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4068 

The market for tooth abscess is driven by factors such as poor dental hygiene due to rise in risk factors such as time constraints due to fast lifestyle, sedentary lifestyles, not brushing your teeth twice a day and lack of flossing etc. Other strong factor is the high sugar diet and junk foods. High sugar diets have high propensity to cause a dental infection whereas junk foods are sticky and retain in the cavities of the teeth for longer times. Drinking sodas can result in slow dissolution of the dental enamel and can lead to rise in cavities due to the weakening of the natural physical barrier of the teeth. The treatment includes draining the abscess followed by antibiotic treatment, performing a root canal etc. Root canal involves the elimination of the infected central tissue, draining the abscess and then filling and sealing the tooth's pulp chamber with a dental filling material. If the infection is severe and the tooth is damaged beyond recovery, then it has to be extracted out completely to avoid any further complications.   

Considering all these factors, the market for dental infection treatment is expected to reach $ 20.5 billion by the end of 2023, the dental infection treatment market size is projected to growing at a CAGR of ~ 8.6 % during 2017-2023.

Key players of Global Dental infection treatment Market:

Key players profiled in the report are Kerr Corporation, Patterson Dental Supply, Inc., Henry Schein, Inc., Pfizer .Inc, Endo Pharmaceuticals, Johnson & Johnson, Taj Pharmaceuticals Limited, Septodont Healthcare India Pvt. Ltd., Bayer HealthCare, Ultradent Products Inc., Bristol-Myers Squibb, Daiichi Sankyo and others.

Segments:

The global dental infection treatment market is segmented on the basis of type, treatment and end users. Based on type, the market has been segmented as periapical abscess, periodontal abscess and others. Based on the treatment, the market has been segmented as drugs (antibiotics, pain killers, others), procedures (root canal, tooth fillings, tooth extraction, others). Based on the end users, the market has been segmented as dentistry clinics, hospitals and others.

Regional analysis

US accounts for the maximum market share due to extensive use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global dental infection treatment. The presence of large device companies in the developed regions is also a major driver of the market. Europe is the second largest market due to large disposable income and rising awareness regarding the health hazards of this condition. Asia Pacific region is expected to have the most future potential and is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.

The report for global dental infection treatment market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/dental-infection-treatment-market-4068 

Huge Growth and Opportunities in Global Nutrigenomics Market Till 2023

 Nutrigenomics Market Size Overview   

The Nutrigenomics Market Size is growing at a tremendous pace. The market is expected to grow at the CAGR of 16.8% during the forecast period and is estimated to reach USD 17,313.5 million by 2023.
Neutrigenomics is the study of interaction of nutrient and genes. It studies the effect of food and their constituents on the genes. The major factors contributing for the growth of the market are rising diabetic and obese population, increasing applications in dermatology, and increasing demand for the advanced diagnostic methods. According to the International Diabetes Federation (2016), 420 million adults were suffering from diabetes which is expected to reach 625 million by 2040. Further, as per the World Health Organization (2014), more than 600 million adults were obese and 1.9 billion adults, were overweight. Moreover, increasing healthcare expenditure, and government support for research & development has fueled the market growth. However, high cost of treatment and need of well qualified physicians may restrain the growth of market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4009 

Nutrigenomics Market Key Players                                                      

Some of the major players in this market are: WellGen Inc. (US), Metagenics, Inc (US), Genomix Nutrition, Inc. (US), Nutrigenomix (US), NutraGene (India), XCODE Life Sciences Pvt. Ltd. (India), Cura Integrative Medicine (Australia)

Nutrigenomics Market Segmentation      

Global nutrigenomics market has been segmented on the basis of products, techniques and application. On the basis of products, the market is categorized into reagents & kits, services. On the basis of techniques, the market is segmented into saliva, buccal swab, blood, others. On the basis of application the market is segmented into obesity, diabetes, anti-aging, chronic diseases.

Nutrigenomics Market Regional analysis                 

Considering the global scenario of the market, America dominates the global nutrigenomics market owing to the presence of huge population suffering from diabetes and obesity. North America holds the largest market share in America nutrigenomics market. According to the Centers for Disease Control and Prevention (2015), in America approximately 9.3% of the total America population is suffering from diabetes. Europe has the second largest market for the nutrigenomics which is followed by Asia Pacific. Presence of well-developed healthcare sector and high healthcare expenditure, the nutrigenomics market in Europe is growing at a CAGR of 17%. Asia Pacific is also witnessing a rapid growth in this market which is mainly due to rapidly increasing awareness of treatments, presence of huge diabetic and obese population and rising healthcare expenditure. Asia Pacific nutrigenomics market is expected to grow at a CAGR of 17.1% during the forecasted period. The Middle East & Africa is expected to have limited growth. Middle East is dominating this market by holding 64.3% of the Middle East & Africa market share.

Key Findings:

• Obesity segment accounts for the largest market share in the global nutrigenomics market while diabetes segment is projected to grow at a CAGR of 17.1% during the forecast period from 2017 – 2023.
• Reagents and kits segment accounts for the largest market share in the global nutrigenomics market by products, this segment is expected to reach USD 10,138.7 Million in 2023
• Americas market is expected to reach USD 6,316.4 Million by 2023

The report for Global Nutrigenomics Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nutrigenomics-market-4009 

Global Foley Catheters Market Analysis 2020 Forecasts to 2023

 

Foley catheter Market Overview

Global Foley catheters market is expected to grow at the CAGR of ~7.8% during the forecast period and is estimated to reach USD 987.3 Million by 2023. A foley catheter is a flexible urinary drainage tube that passes through the urethra and into the bladder by a small, water-inflated balloon. Increasing prevalence of urologic diseases, hospitalization, new product development and launches, large product portfolio, wide acceptance, and increasing demand from emerging market is driving the growth for global foley catheter market. Major players of this market are investing in research and innovative product development to improve existing structure and usage of the foley catheters. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/922 

Key Findings

Latex type of material segment accounts for the largest market share in the global foley catheters market while hydrophilic polymer coated latex segment is projected to grow at a CAGR of 8.3% during the forecast period from 2017 – 2023.

2-way catheters segment accounts for the largest market share in the global foley catheters market by type, this market is expected to reach USD 527.4 in 2023

China Foley catheters market size is expected to grow at a CAGR of 10.0% during the forecast period.

Segments 

Global Foley catheters market has been segmented on the basis of type of material latex, silicone, silicone elastomer coated latex, hydrophilic polymer coated latex, Polytetrafluoroethylene PTFE (Teflon) coated latex, and others. On the basis of type, it is segmented into 2-way catheters, 3-way catheters, 4-way catheters, and others. On the basis of end user, it is segmented into medical research center, hospitals, and ambulatory surgery centers.

Regional Analysis of Global Foley Catheters Market 

Considering the global scenario of the market, North America is the top contributor for foley catheters. Due to large amount of money invested in R&D and advanced products development, the North American Foley catheters market was valued USD 228.8 million in 2016. Europe is not far behind and accounts for the second largest market share owing to adoption of new and advanced technologies and products; it is expected to reach USD 306.1 Million by 2023.Germany is dominating this market while UK is the fastest growing Foley catheters market in Europe. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly increasing prevalence of various urologic diseases and rising healthcare expenditure. Asia Pacific foley catheters market is expected to grow at a CAGR of 9.3% during the forecast period. Middle East & Africa is expected to have limited growth. Middle East is dominating this market by holding 69.3% of the market share.

Key Players for Global Foley Catheters Market   

Some of the key players in this market are: B. Braun Melsungen AG (Germany), Coloplast Ltd (Denmark), Cook (US), Teleflex (US), Medline Industries, Inc. (US), and Medtronic (Republic of Ireland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/foley-catheter-market-922   

Dental Wax Market Robust Expansion by Top Key Players, Demand and Supply to 2023

 Market scenario

Dental wax is a mixture of different type of waxes with synthetic additives, used in dentistry for casting, sizing and mapping of structures and jaw relations, laboratory work and as lubricants to relieve friction associated with braces and other dental implants. Dental wax is an opaque hydrophobic material, mostly produced from petroleum and vegetable sources, which softens on being pressed or heated. Self-setting dental waxes are used for the purpose of mapping dental structures during the manufacturing of dental caps and custom sized implants. Softer dental waxes are used to relieve discomfort caused by orthodontic implants such as braces, wires, etc. They also relieve from irritation caused by rubbing of the brace or tooth arch wire against the cheek. Synthetic materials such as silicon based waxes have however encroached on the natural sources. A variety of additives are added to modify their physical properties to make them suitable for their intended use. The important properties of dental waxes are their melting point, flow properties etc. Melting range, and flow improve the product characteristics which causes the market to rise due to increased demand.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4087 

Increasing use of dental fixtures and treatments, rising awareness of dental diseases, increasing penetration of dentistry in the healthcare setup of many countries, rising use of dental implants drive the growth of the market. Additionally, positive influence of media and fashion industry on rising dental aesthetics demand and increasing awareness adding fuel to the dental waxes market.

Various disadvantages, for instance, discomfort due to hydrophobic nature and reduction in mouth movements are likely to affect market negatively. Furthermore, dental wax extend the healing time due to their tissue softening effect and hinder the natural hardening tissue process, which, in turn, may hamper the demand for the dental wax over the review period.

The global dental waxes market is expected to reach US$ 1.2 billion by 2023, and the market is projected to grow at a CAGR of ~ 5.2 % during the forecast period 2017-2023.

Research Methodology

Key Players in the Global Dental Wax Market

Some of key players profiled in the report are Kerr Corporation, Pyrax Polymars, C.J. Robinson Company, Inc., Metrodent Ltd., DWS Systems , Bilkim Ltd. Co., Carmel Industries, Solstice T&I, Bracon Dental and others.

Segments

The global dental wax market has been segmented on the basis of sources, applications, and end users.

Based on source, the market has been segmented as the mineral wax, animal wax, plant wax and synthetic wax. The synthetic wax is further sub-segmented into polyethylene, hydrocarbon, and others.

Based on the applications, the market has been segmented as pattern wax, processing wax, impression wax, healing wax and others. The pattern wax is sub-segmented into lay wax, casting wax, base plate wax and others. The processing wax is sub-segmented into lay wax, sticky wax, boxing wax, and others. The impression wax is sub-segmented into corrective wax, bite plate wax, healing wax, and others.

Based on the end users, the market has been segmented as dentist clinics, academic and research centers and others.

Regional analysis

The Americas accounts for the significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global dental wax market. Also, the concentration of the major dental product manufacturers in the developed countries of this region is adding fuel to the market.

Europe is the second largest market in the globe due to a high disposable income and rising awareness about the dental treatment.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead the market due to unmet needs during the forecast period.

Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

The report for Global dental wax market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/dental-wax-market-4092  

Mal Seizure Market 2020 - Industry Growth, Analysis, Size and Share to 2023

 Market scenario

Epilepsy is a group of neurological disorders characterized by brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe had epilepsy in 2015 across the globe. Grand mal seizures or tonic–clonic seizures are a type of generalized seizures, which affect the entire brain and are the most common type of epileptic seizures. Grand mal seizures are caused by neurotransmitter imbalances, which can also be influenced by fatigue, lack of sleep, hypertension, stress, intense lighting, rapid motion, blood sugar level, anxiety, etc. The grand mal seizures consist of two phases, the tonic phase and the clonic phase. The tonic phase involves loss of consciousness and muscle twitching and the phase usually last only for a few seconds. The clonic phase consists of rapid muscle contraction and relaxation resulting in convulsions.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4087 

Development of better tolerated third generation drugs, increasing screening of patients, and growing geriatric population- they are more susceptible to epilepsy- drive the growth of the market. Increased patent expiry for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018), unknown origin and action mechanism  of epilepsy, and concurrent lack of innovative drugs are likely to affect the market growth negatively. The market is also constrained by the poor efficacy and efficiency of most of the anti-epileptic drugs. A sizeable segment of patients respond very poorly or none at all to main line drugs such as the Gamma Aminobutyric Acid Modulators and ion channel blockers. These drugs have serious adverse effect on the patient such as depression, and suicidal behaviour, dizziness, fatigue, weight gain, etc. Social stigma associated with the epilepsy, especially, in the developing countries may hamper the market over the forecast period.

The global grand mal seizures market is expected to reach US$ 2.8 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.2 % during the forecast period 2017-2023.

Segments

The global grand mal seizure market has been segmented on the basis of drug generation, drug class, surgery, diagnosis, and end users. Based on drug generation, the market has been segmented as the first generation, the second generation, and the third generation. Based on the drug class, the market has been segmented as barbiturates, hydantoin, cyclic gaba analogues, phenyltriazine, iminostilbenes, aliphatic carboxylic acid, benzodiazepines, and others. Based on the surgery, the market has been segmented as resective surgery, multiple subpial transection, hemispherectomy, corpus callosotomy, and others. Based on the diagnosis, the market has been segmented as electroencephalogram (EEG), magnetic resonance imaging (MRI), computed tomography (CT), blood tests, and others. Based on the end users, the market has been segmented as hospitals, neurological centers, academic and research center, and others.

Regional analysis

The Americas accounts for the significant market share owing to extensive use of medications and greater expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global grand mal seizures market. The concentration of the major medical diagnostic device manufacturers in the developed regions is also adding fuel to the market. Europe is the second largest market due to a high disposable income and rising awareness about the grand mal seizures.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead the market during the forecast period.

Gulf nations, Saudi Arabia and the UAE, drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Key Players in the Global Grand Mal Seizure Market

Some of key players profiled in the report are Pfizer, Inc., Johnson & Johnson Services, Inc., UCB Celltech, Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Sanofi. Shire Pharmaceuticals Limited, and Teva Pharmaceutical Industries.

The report for Global Grand mal seizure market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/grand-mal-seizure-market-4087